BBIO insider transactions
BridgeBio Pharma Inc. (BBIO) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for BBIO
- Chief Executive Officer Kumar Neil sold $5,413,289 worth of shares (80,000 units at $67.67) as part of a pre-agreed trading plan (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $1,812,522 worth of shares (26,103 units at $69.44) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 243,327 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- President and CFO Trimarchi Thomas covered exercise/tax liability with 22,781 shares and sold $888,419 worth of shares (13,651 units at $65.08) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 359,194 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil converted options into 71,215 shares and covered exercise/tax liability with 36,236 shares, increasing direct ownership by 15% to 269,430 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel covered exercise/tax liability with 4,714 shares, decreasing direct ownership by 4% to 129,401 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Scott Randal W. exercised 10,000 shares at a strike of $16.75 and sold $671,456 worth of shares (10,000 units at $67.15) as part of a pre-agreed trading plan (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $5,392,243 worth of shares (80,000 units at $67.40) as part of a pre-agreed trading plan (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel sold $143,160 worth of shares (2,000 units at $71.58) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 134,115 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- SEC Form 4 filed by Kumar Neil4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- SEC Form 4 filed by Trimarchi Thomas4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- SEC Form 4 filed by Apuli Maricel4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- SEC Form 4 filed by Kumar Neil4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $5,501,068 worth of shares (80,000 units at $68.76) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Valantine Hannah exercised 8,671 shares at a strike of $27.36 and sold $624,312 worth of shares (8,671 units at $72.00) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Ellis Andrea exercised 64,921 shares at a strike of $8.45 and sold $4,211,302 worth of shares (64,921 units at $64.87) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Valantine Hannah exercised 25,484 shares at a strike of $48.45 and sold $1,717,781 worth of shares (25,484 units at $67.41) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel sold $132,000 worth of shares (2,000 units at $66.00), decreasing direct ownership by 2% to 121,945 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $2,002,717 worth of shares (28,053 units at $71.39), decreasing direct ownership by 11% to 234,451 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil converted options into 64,698 shares and covered exercise/tax liability with 30,970 shares, increasing direct ownership by 15% to 262,504 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel covered exercise/tax liability with 4,349 shares and sold $37,898 worth of shares (510 units at $74.31), decreasing direct ownership by 4% to 123,945 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- President and CFO Trimarchi Thomas sold $1,016,147 worth of shares (13,600 units at $74.72) and covered exercise/tax liability with 18,819 shares, decreasing direct ownership by 9% to 336,585 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Scott Randal W. exercised 10,000 shares at a strike of $16.75 and sold $754,557 worth of shares (10,000 units at $75.46) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $5,748,666 worth of shares (80,000 units at $71.86) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $6,043,168 worth of shares (80,000 units at $75.54) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil converted options into 60,975 shares, covered exercise/tax liability with 30,964 shares and sold $2,239,902 worth of shares (30,011 units at $74.64) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- President and CFO Trimarchi Thomas covered exercise/tax liability with 13,826 shares, decreasing direct ownership by 4% to 369,004 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel covered exercise/tax liability with 2,003 shares, decreasing direct ownership by 2% to 128,294 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel sold $148,520 worth of shares (2,000 units at $74.26), decreasing direct ownership by 2% to 130,297 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $5,908,476 worth of shares (80,000 units at $73.86) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $1,722,224 worth of shares (26,156 units at $65.84), decreasing direct ownership by 10% to 228,776 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Lo Andrew sold $6,319,662 worth of shares (95,599 units at $66.11), decreasing direct ownership by 74% to 14,089 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Scott Randal W. exercised 10,000 shares at a strike of $16.75 and sold $666,465 worth of shares (10,000 units at $66.65) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil converted options into 64,697 shares and covered exercise/tax liability with 32,855 shares, increasing direct ownership by 14% to 254,932 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- President and CFO Trimarchi Thomas covered exercise/tax liability with 21,317 shares and sold $1,125,404 worth of shares (16,934 units at $66.46), decreasing direct ownership by 9% to 382,830 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel covered exercise/tax liability with 4,781 shares, decreasing direct ownership by 3% to 132,297 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Valantine Hannah exercised 25,484 shares at a strike of $48.45 and sold $1,683,728 worth of shares (25,484 units at $66.07) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $4,983,111 worth of shares (80,000 units at $62.29) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Daniels Ronald J exercised 61,031 shares at a strike of $34.65 and sold $3,888,999 worth of shares (61,031 units at $63.72) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Mccormick Frank sold $13,206,528 worth of shares (198,359 units at $66.58) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Mccormick Frank sold $106,665 worth of shares (1,641 units at $65.00) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $4,383,442 worth of shares (80,000 units at $54.79) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Mccormick Frank sold $3,933,544 worth of shares (74,000 units at $53.16) and exercised 74,000 shares at a strike of $11.92 (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $4,175,835 worth of shares (80,000 units at $52.20) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- President and CFO Trimarchi Thomas sold $2,090,081 worth of shares (42,237 units at $49.48), decreasing direct ownership by 9% to 421,081 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $1,276,927 worth of shares (26,156 units at $48.82), decreasing direct ownership by 10% to 223,090 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel covered exercise/tax liability with 4,781 shares, decreasing direct ownership by 3% to 137,078 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- President and CFO Trimarchi Thomas covered exercise/tax liability with 21,317 shares and sold $871,722 worth of shares (17,353 units at $50.23), decreasing direct ownership by 8% to 463,318 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil converted options into 64,697 shares and covered exercise/tax liability with 32,855 shares, increasing direct ownership by 15% to 249,246 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Homcy Charles J sold $13,912,443 worth of shares (300,000 units at $46.37), decreasing direct ownership by 25% to 916,674 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel sold $45,440 worth of shares (1,000 units at $45.44), decreasing direct ownership by 0.70% to 141,859 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $3,666,949 worth of shares (80,000 units at $45.84) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Ellis Andrea sold $841,183 worth of shares (17,167 units at $49.00) and exercised 17,167 shares at a strike of $16.75 (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $3,410,450 worth of shares (80,000 units at $42.63) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Large owner Viking Global Investors Lp sold $154,000,000 worth of shares (3,500,000 units at $44.00) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Homcy Charles J gifted 20,000 shares, decreasing direct ownership by 2% to 1,216,674 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Valantine Hannah sold $207,327 worth of shares (4,707 units at $44.05), decreasing direct ownership by 24% to 7,465 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Amendment: Director Valantine Hannah bought $24,948 worth of shares (1,752 units at $14.24), increasing direct ownership by 114% to 3,294 units (SEC Form 4)4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Amendment: Director Valantine Hannah bought $30,028 worth of shares (2,338 units at $12.84) (SEC Form 4)4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Mccormick Frank sold $4,422,800 worth of shares (100,000 units at $44.23) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Lo Andrew was granted 6,589 shares, increasing direct ownership by 14% to 54,688 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)